[Gene therapy for cardiomyopathy].
Cardiac transplantation has become accepted therapy for a number of patients with severe cardiomyopathy. The cellular cardiomyoplasty is expected as an alternative therapy for cardiomyopathy. The experimental foundation was laid for the approach to cellular cardiomyoplasty--the molecular and cellular treatment of cardiomyopathy by augmentation, regeneration or replacement of cardiomyocytes--by experiments in cardiac gene transfer and transgenic animals. Recently, cardiomyocyte has been reported to be generated from embryonic stem cell or marrow stromal cell in vitro. However, differentiation from non-cardiomyocyte to cardiomyocyte cannot be controlled completely yet. It is now under investigation mainly in an experimental setting. For successful gene therapy, not only characterization of proper targets but also elimination of undesirable side effects are indispensable.
Morita
H
H
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo.
D000818:Animals; D009202:Cardiomyopathies / Q000628:therapy*; D018797:Cell Cycle Proteins / Q000235:genetics; D002454:Cell Differentiation; D002455:Cell Division; D017690:Cell Transplantation; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D009206:Myocardium / Q000166:cytology; D013234:Stem Cells; D014157:Transcription Factors / Q000235:genetics
D018797:Cell Cycle Proteins; D014157:Transcription Factors